A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2021-08-12
Target enrollment:
Participant gender:
Summary
The purpose of a phase Ib study is to find out the best or maximum tolerated dose of a
medication or combination of medications. Therefore, the purpose of this study is to decide
the best dose of the study drug, Debio 1347, that can be given in combination with the
standard hormonal drug, fulvestrant. Debio 1347 and fulvestrant could shrink the cancer but
it could also cause side effects. This study tells us about the side effects of these drugs
when given in this new combination, and how often they occur.